Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NOVAVAX INCNVAX · Entity 4632 | President, R&D | March 06, 2023 | March 14, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NOVAVAX INC
Report date March 06, 2023 · Filed March 14, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,473 |
Reported balance
After 2023-03-06 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-03-06 · Purchase · Acquired 3,000 · Balance 11,473 F1: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.2658 to $7.65, inclusive. The reporting person undertakes to provide to Novavax, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. F2: Includes 464 shares acquired on January 31, 2023 under the Company's Amended and Restated 2013 Employee Stock Purchase Plan, as amended. |
| Common StockSEC Table I · non-derivative | Direct | 13,473 |
Reported balance
After 2023-03-07 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2023-03-07 · Purchase · Acquired 2,000 · Balance 13,473 F3: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.0089 to $7.0594, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. |
| Common StockSEC Table I · non-derivative | Direct | 14,473 |
Reported balance
After 2023-03-10 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2023-03-10 · Purchase · Acquired 1,000 · Balance 14,473 F4: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.45 to $6.55, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. |
| Common StockSEC Table I · non-derivative | Direct | 20,771 |
Reported balance
After 2023-03-10 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2023-03-10 · Exercise / conversion · Acquired 6,298 · Balance 20,771 F5: The shares were received by the reporting person in connection with vesting of restricted stock units ("RSUs"). |
| Common StockSEC Table I · non-derivative | Direct | 18,339 |
Reported balance
After 2023-03-10 transaction · row 5
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 5 · 2023-03-10 · Tax withholding · Disposed 2,432 · Balance 18,339 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 12,596 |
Reported balance
After 2023-03-10 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-03-10 · Exercise / conversion · Disposed 6,298 · Balance 12,596 F6: Each RSU represents a contingent right to receive one share of the Company common stock. F7: The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the March 10, 2022 grant date, in each case subject to continued employment through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.2658 to $7.65, inclusive. The reporting person undertakes to provide to Novavax, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
F2: Includes 464 shares acquired on January 31, 2023 under the Company's Amended and Restated 2013 Employee Stock Purchase Plan, as amended.
F3: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.0089 to $7.0594, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
F4: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.45 to $6.55, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
F5: The shares were received by the reporting person in connection with vesting of restricted stock units ("RSUs").
F6: Each RSU represents a contingent right to receive one share of the Company common stock.
F7: The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the March 10, 2022 grant date, in each case subject to continued employment through such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 16, 2021 Filed Nov 17, 2021 22:25 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 1,326 | $168.91 | $223,969.36 |
DisclosureSEC source: 0001209191-21-065181 · doc4.xml · nonDerivative · entry 7 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,013 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $168.61 to $169.54, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| November 16, 2021 Filed Nov 17, 2021 22:25 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 1,472 | $167.95 | $247,225.20 |
DisclosureSEC source: 0001209191-21-065181 · doc4.xml · nonDerivative · entry 6 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,339 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $167.49 to $168.42, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| November 16, 2021 Filed Nov 17, 2021 22:25 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 500 | $166.89 | $83,446.00 |
DisclosureSEC source: 0001209191-21-065181 · doc4.xml · nonDerivative · entry 5 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,811 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $166.33 to $167.22, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| November 16, 2021 Filed Nov 17, 2021 22:25 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 8,250 | $19.08 | $157,410.00 |
DisclosureSEC source: 0001209191-21-065181 · doc4.xml · nonDerivative · entry 4 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,311 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 22:25 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionStock Option (Right to Buy) · Derivative | 662 | $0.00 Strike: $46.00 | $0.00 |
DisclosureSEC source: 0001209191-21-065181 · doc4.xml · derivative · entry 11 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,606 Underlying: Common Stock · 662 shares Expires 2028-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F9 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option grant under the Plan vested on the first anniversary of the December 13, 2018 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date. Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 22:25 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionStock Option (Right to Buy) · Derivative | 521 | $0.00 Strike: $27.60 | $0.00 |
DisclosureSEC source: 0001209191-21-065181 · doc4.xml · derivative · entry 10 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,024 Underlying: Common Stock · 521 shares Expires 2027-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F8 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option grant under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan") vested on the first anniversary of the December 15, 2017 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date. Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 22:25 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 1,183 | $172.02 | $203,495.76 |
DisclosureSEC source: 0001209191-21-065181 · doc4.xml · nonDerivative · entry 3 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,061 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $172.01 to $172.07, inclusive. The reporting person undertakes to provide to Novavax, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 22:25 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 662 | $46.00 | $30,452.00 |
DisclosureSEC source: 0001209191-21-065181 · doc4.xml · nonDerivative · entry 2 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,244 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 22:25 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 521 | $27.60 | $14,379.60 |
DisclosureSEC source: 0001209191-21-065181 · doc4.xml · nonDerivative · entry 1 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,582 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| November 09, 2021 Filed Nov 12, 2021 22:02 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,250 | $0.00 Strike: $19.08 | $0.00 |
DisclosureSEC source: 0001209191-21-064260 · doc4.xml · derivative · entry 10 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,500 Underlying: Common Stock · 8,250 shares Expires 2030-04-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F9 · derivative.exercise_date: On April 17, 2020, the reporting person was granted an option to purchase 165,000 shares of common stock of the Company pursuant to the Company's Amended and Restated 2015 Stock Incentive Plan, as amended. The vesting of the shares subject to this option grant is subject to the satisfaction of a performance-based vesting requirement, followed by time-based vesting. The performance metric required that the Company initiate a COVID-19 Phase 2 clinical trial within twelve (12) months of the grant date, which occurred when the Company initiated its Phase 2 clinical trial of NVX-CoV2373 in the U.S. on August 24, 2020. Following that event, fifty percent (50%) of the shares vested on August 24, 2021, the first anniversary of the initiation date, and the remaining fifty percent (50%) of the shares will vest on August 24, 2022, the second anniversary of the initiation date subject to continued employment through such vesting date. Read SEC document |
| November 09, 2021 Filed Nov 12, 2021 22:02 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 100 | $171.48 | $17,148.00 |
DisclosureSEC source: 0001209191-21-064260 · doc4.xml · nonDerivative · entry 9 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,061 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| November 09, 2021 Filed Nov 12, 2021 22:02 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 400 | $170.55 | $68,219.00 |
DisclosureSEC source: 0001209191-21-064260 · doc4.xml · nonDerivative · entry 8 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,161 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F8 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $170.28 to $170.76, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| November 09, 2021 Filed Nov 12, 2021 22:02 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 1,478 | $169.54 | $250,582.48 |
DisclosureSEC source: 0001209191-21-064260 · doc4.xml · nonDerivative · entry 7 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,561 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $169.27 to $169.87, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| November 09, 2021 Filed Nov 12, 2021 22:02 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 672 | $168.46 | $113,204.38 |
DisclosureSEC source: 0001209191-21-064260 · doc4.xml · nonDerivative · entry 6 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,039 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $168.20 to $168.92, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| November 09, 2021 Filed Nov 12, 2021 22:02 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 2,000 | $167.76 | $335,517.00 |
DisclosureSEC source: 0001209191-21-064260 · doc4.xml · nonDerivative · entry 5 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,711 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $167.09 to $168.08, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| November 09, 2021 Filed Nov 12, 2021 22:02 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 1,800 | $166.55 | $299,782.98 |
DisclosureSEC source: 0001209191-21-064260 · doc4.xml · nonDerivative · entry 4 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,711 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $166.09 to $167.06, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| November 09, 2021 Filed Nov 12, 2021 22:02 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 1,400 | $165.72 | $232,013.04 |
DisclosureSEC source: 0001209191-21-064260 · doc4.xml · nonDerivative · entry 3 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,511 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $165.09 to $166.03, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| November 09, 2021 Filed Nov 12, 2021 22:02 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 400 | $164.23 | $65,693.00 |
DisclosureSEC source: 0001209191-21-064260 · doc4.xml · nonDerivative · entry 2 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,911 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $164.02 to $164.73, inclusive. The reporting person undertakes to provide to Novavax, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| November 09, 2021 Filed Nov 12, 2021 22:02 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 8,250 | $19.08 | $157,410.00 |
DisclosureSEC source: 0001209191-21-064260 · doc4.xml · nonDerivative · entry 1 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,311 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| November 02, 2021 Filed Nov 4, 2021 21:22 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,250 | $0.00 Strike: $19.08 | $0.00 |
DisclosureSEC source: 0001209191-21-062976 · doc4.xml · derivative · entry 19 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,750 Underlying: Common Stock · 8,250 shares Expires 2030-04-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F17 · derivative.exercise_date: On April 17, 2020, the reporting person was granted an option to purchase 165,000 shares of common stock of the Company pursuant to the Plan. The vesting of the shares subject to this option grant is subject to the satisfaction of a performance-based vesting requirement, followed by time-based vesting. The performance metric required that the Company initiate a COVID-19 Phase 2 clinical trial within twelve (12) months of the grant date, which occurred when the Company initiated its Phase 2 clinical trial of NVX-CoV2373 in the U.S. on August 24, 2020. Following that event, fifty percent (50%) of the shares vested on August 24, 2021, the first anniversary of the initiation date, and the remaining fifty percent (50%) of the shares will vest on August 24, 2022, the second anniversary of the initiation date subject to continued employment through such vesting date. Read SEC document |
| November 02, 2021 Filed Nov 4, 2021 21:22 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 100 | $197.51 | $19,751.00 |
DisclosureSEC source: 0001209191-21-062976 · doc4.xml · nonDerivative · entry 18 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,061 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| November 02, 2021 Filed Nov 4, 2021 21:22 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 200 | $196.24 | $39,248.00 |
DisclosureSEC source: 0001209191-21-062976 · doc4.xml · nonDerivative · entry 17 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,161 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F16 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $195.98 to $196.50, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| November 02, 2021 Filed Nov 4, 2021 21:22 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 378 | $195.54 | $73,913.21 |
DisclosureSEC source: 0001209191-21-062976 · doc4.xml · nonDerivative · entry 16 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,361 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F15 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $194.98 to $195.90, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| November 02, 2021 Filed Nov 4, 2021 21:22 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 300 | $194.40 | $58,320.00 |
DisclosureSEC source: 0001209191-21-062976 · doc4.xml · nonDerivative · entry 15 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,739 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F14 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $193.83 to $194.79, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| November 02, 2021 Filed Nov 4, 2021 21:22 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 400 | $193.16 | $77,262.00 |
DisclosureSEC source: 0001209191-21-062976 · doc4.xml · nonDerivative · entry 14 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,039 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F13 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $192.62 to $193.61, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| November 02, 2021 Filed Nov 4, 2021 21:22 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 100 | $190.29 | $19,029.00 |
DisclosureSEC source: 0001209191-21-062976 · doc4.xml · nonDerivative · entry 13 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,439 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| November 02, 2021 Filed Nov 4, 2021 21:22 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 300 | $188.33 | $56,499.00 |
DisclosureSEC source: 0001209191-21-062976 · doc4.xml · nonDerivative · entry 12 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,539 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F12 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $188.27 to $188.37, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| November 02, 2021 Filed Nov 4, 2021 21:22 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 300 | $187.26 | $56,177.01 |
DisclosureSEC source: 0001209191-21-062976 · doc4.xml · nonDerivative · entry 11 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,839 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F11 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $186.98 to $187.71, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| November 02, 2021 Filed Nov 4, 2021 21:22 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 500 | $186.09 | $93,047.00 |
DisclosureSEC source: 0001209191-21-062976 · doc4.xml · nonDerivative · entry 10 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,139 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F10 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $185.71 to $186.60, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| November 02, 2021 Filed Nov 4, 2021 21:22 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 302 | $184.82 | $55,815.25 |
DisclosureSEC source: 0001209191-21-062976 · doc4.xml · nonDerivative · entry 9 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,639 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F9 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $184.57 to $185.24, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| November 02, 2021 Filed Nov 4, 2021 21:22 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 800 | $183.58 | $146,860.00 |
DisclosureSEC source: 0001209191-21-062976 · doc4.xml · nonDerivative · entry 8 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,941 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F8 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $183.32 to $183.93, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| November 02, 2021 Filed Nov 4, 2021 21:22 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 600 | $182.58 | $109,546.98 |
DisclosureSEC source: 0001209191-21-062976 · doc4.xml · nonDerivative · entry 7 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,741 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $182.29 to $182.99, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| November 02, 2021 Filed Nov 4, 2021 21:22 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 670 | $181.55 | $121,637.29 |
DisclosureSEC source: 0001209191-21-062976 · doc4.xml · nonDerivative · entry 6 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,341 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $181.17 to $181.89, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| November 02, 2021 Filed Nov 4, 2021 21:22 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 600 | $180.41 | $108,247.98 |
DisclosureSEC source: 0001209191-21-062976 · doc4.xml · nonDerivative · entry 5 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,011 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $179.96 to $180.80, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| November 02, 2021 Filed Nov 4, 2021 21:22 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 900 | $179.09 | $161,180.01 |
DisclosureSEC source: 0001209191-21-062976 · doc4.xml · nonDerivative · entry 4 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,611 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $178.75 to $179.67, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| November 02, 2021 Filed Nov 4, 2021 21:22 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 1,200 | $178.12 | $213,749.04 |
DisclosureSEC source: 0001209191-21-062976 · doc4.xml · nonDerivative · entry 3 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,511 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $177.52 to $178.51, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| November 02, 2021 Filed Nov 4, 2021 21:22 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 600 | $177.12 | $106,269.00 |
DisclosureSEC source: 0001209191-21-062976 · doc4.xml · nonDerivative · entry 2 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,711 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $176.47 to $177.41, inclusive. The reporting person undertakes to provide to Novavax, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| November 02, 2021 Filed Nov 4, 2021 21:22 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 8,250 | $19.08 | $157,410.00 |
DisclosureSEC source: 0001209191-21-062976 · doc4.xml · nonDerivative · entry 1 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,311 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| October 29, 2021 Filed Nov 2, 2021 23:02 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 26 | $152.16 | $3,956.28 |
DisclosureSEC source: 0001209191-21-062506 · doc4.xml · nonDerivative · entry 6 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,061 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.78 to $152.28, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| October 29, 2021 Filed Nov 2, 2021 23:02 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 16 | $149.64 | $2,394.24 |
DisclosureSEC source: 0001209191-21-062506 · doc4.xml · nonDerivative · entry 5 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,087 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| October 29, 2021 Filed Nov 2, 2021 23:02 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 353 | $148.99 | $52,591.74 |
DisclosureSEC source: 0001209191-21-062506 · doc4.xml · nonDerivative · entry 4 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,103 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $148.51 to $149.44, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| October 29, 2021 Filed Nov 2, 2021 23:02 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 138 | $148.08 | $20,435.23 |
DisclosureSEC source: 0001209191-21-062506 · doc4.xml · nonDerivative · entry 3 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,456 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $147.50 to $148.41, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| October 29, 2021 Filed Nov 2, 2021 23:02 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 108 | $146.51 | $15,822.66 |
DisclosureSEC source: 0001209191-21-062506 · doc4.xml · nonDerivative · entry 2 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,594 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $146.12 to $147.00, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| October 29, 2021 Filed Nov 2, 2021 23:02 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 39 | $145.41 | $5,670.90 |
DisclosureSEC source: 0001209191-21-062506 · doc4.xml · nonDerivative · entry 1 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,702 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $145.12 to $145.52, inclusive. The reporting person undertakes to provide to Novavax, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| October 26, 2021 Filed Oct 28, 2021 21:09 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionStock Appreciation Right · Derivative | 1,378 | $0.00 Strike: $5.95 | $0.00 |
DisclosureSEC source: 0001209191-21-061919 · doc4.xml · derivative · entry 13 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,673 Underlying: Common Stock · 1,378 shares Expires 2029-09-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · kind: The reporting person received 680 shares of common stock upon the net exercise of 1,378 stock appreciation rights under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"). The reporting person forfeited 61 shares of common stock underlying the stock appreciation rights representing the base value and 637 shares of common stock underlying the stock appreciation rights to satisfy the withholding tax obligations resulting from the exercise, using the closing stock price on October 26, 2021 of $134.99. F10 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this stock appreciation right grant under the Plan vested on the first anniversary of the September 26, 2019 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date. Read SEC document |
| October 26, 2021 Filed Oct 28, 2021 21:09 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,250 | $0.00 Strike: $19.08 | $0.00 |
DisclosureSEC source: 0001209191-21-061919 · doc4.xml · derivative · entry 12 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,000 Underlying: Common Stock · 8,250 shares Expires 2030-04-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F9 · derivative.exercise_date: On April 17, 2020, the reporting person was granted an option to purchase 165,000 shares of common stock of the Company pursuant to the Plan. The vesting of the shares subject to this option grant is subject to the satisfaction of a performance-based vesting requirement, followed by time-based vesting. The performance metric required that the Company initiate a COVID-19 Phase 2 clinical trial within twelve (12) months of the grant date, which occurred when the Company initiated its Phase 2 clinical trial of NVX-CoV2373 in the U.S. on August 24, 2020. Following that event, fifty percent (50%) of the shares vested on August 24, 2021, the first anniversary of the initiation date, and the remaining fifty percent (50%) of the shares will vest on August 24, 2022, the second anniversary of the initiation date subject to continued employment through such vesting date. Read SEC document |
| October 26, 2021 Filed Oct 28, 2021 21:09 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,084 | $0.00 Strike: $5.95 | $0.00 |
DisclosureSEC source: 0001209191-21-061919 · doc4.xml · derivative · entry 11 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,917 Underlying: Common Stock · 2,084 shares Expires 2029-09-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F8 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option grant under the Plan vested on the first anniversary of the September 26, 2019 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date. Read SEC document |
| October 26, 2021 Filed Oct 28, 2021 21:09 UTC | NOVAVAX INC NVAX · Entity 4632 | Tax withholdingCommon Stock | 637 | $134.99 | $85,988.63 |
DisclosureSEC source: 0001209191-21-061919 · doc4.xml · nonDerivative · entry 10 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,741 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · kind: The reporting person received 680 shares of common stock upon the net exercise of 1,378 stock appreciation rights under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"). The reporting person forfeited 61 shares of common stock underlying the stock appreciation rights representing the base value and 637 shares of common stock underlying the stock appreciation rights to satisfy the withholding tax obligations resulting from the exercise, using the closing stock price on October 26, 2021 of $134.99. Read SEC document |
| October 26, 2021 Filed Oct 28, 2021 21:09 UTC | NOVAVAX INC NVAX · Entity 4632 | Disposition to issuerCommon Stock | 61 | $134.99 | $8,234.39 |
DisclosureSEC source: 0001209191-21-061919 · doc4.xml · nonDerivative · entry 9 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,378 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · kind: The reporting person received 680 shares of common stock upon the net exercise of 1,378 stock appreciation rights under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"). The reporting person forfeited 61 shares of common stock underlying the stock appreciation rights representing the base value and 637 shares of common stock underlying the stock appreciation rights to satisfy the withholding tax obligations resulting from the exercise, using the closing stock price on October 26, 2021 of $134.99. Read SEC document |
| October 26, 2021 Filed Oct 28, 2021 21:09 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 1,378 | $5.95 | $8,199.10 |
DisclosureSEC source: 0001209191-21-061919 · doc4.xml · nonDerivative · entry 8 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,439 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · kind: The reporting person received 680 shares of common stock upon the net exercise of 1,378 stock appreciation rights under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"). The reporting person forfeited 61 shares of common stock underlying the stock appreciation rights representing the base value and 637 shares of common stock underlying the stock appreciation rights to satisfy the withholding tax obligations resulting from the exercise, using the closing stock price on October 26, 2021 of $134.99. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.